Drug Recall
Ongoing
Historical recordClass III
Cisatracurium Besylate Injection USP, 10 mg/5 mL* (2mg/mL), 10 x 5 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, Single-dose 5 mL vial NDC 70069-141-01; 10x5 mL single dose vial per Carton NDC 70069-141-10.
by SOMERSET THERAPEUTICS LLC
- Reason
- Subpotent product:out of specification assay results observed during long term stability testing.
- Recall initiated
- November 26, 2025
- Reported by FDA
- December 24, 2025
- Distribution
- Nationwide in the USA
View recall →
Drug Recall
Ongoing
Historical recordClass II
Baclofen Tablets USP, 10 mg, 1000-count bottles, Rx only, Marketed by: GSMS, Incorporated, CA 93012 USA. NDC 51407-973-10
by Golden State Medical Supply Inc.
- Reason
- Presence of Foreign Tablets/Capsules
- Recall initiated
- November 26, 2025
- Reported by FDA
- December 24, 2025
- Distribution
- Nationwide within the USA
View recall →
Drug Recall
Ongoing
Historical recordClass II
OraVerse, (Phentolamine Mesylate) Injection, 0.4 mg/1.7mL, packaged in a carton containing 10 cartridges, 0.4 mg/1.7mL, Rx only, Made in Canada by Novocol Pharmaceutical of Canada, Inc., Distributed by Septodont, Inc., Louisville, Co, 80027, NDC 0362-0101-10
by Novocol Pharmaceutical of Canada, Inc.
- Reason
- Defective container: cracked/broken cartridges
- Recall initiated
- October 31, 2025
- Reported by FDA
- December 24, 2025
- Distribution
- U.S.A. Nationwide
View recall →
Drug Recall
Ongoing
Historical recordClass II
Cook-Walte, Carbocaine 3% (30 mg/mL), (mepivacaine hydrochloride Injection, USP), packaged in a carton containing 50 Single-Dose Cartridges, 1.7 mL, Rx only, Manufactured by Novocol Pharmaceutical of Canada, Inc., NDC 0362-0753-05.
by Novocol Pharmaceutical of Canada, Inc.
- Reason
- Defective container: cracked/broken cartridges
- Recall initiated
- October 31, 2025
- Reported by FDA
- December 24, 2025
- Distribution
- U.S.A. Nationwide
View recall →
Drug Recall
Ongoing
Historical recordClass II
Benco dental Graham CHEMICAL CO., Mepivacaine HCI 3% (30 mg/mL) Injection, [Mepivacaine HCI Injection, USP], packaged in a carton containing 50 single-dose Cartridges, 1.7 mL each, Rx only, Distributed by Benco Dental 295 Center Point Blvd, Pittston, PA 18640, Manufactured by Novocol Pharmaceutical of Canada, Inc., NDC 66975-406-51.
by Novocol Pharmaceutical of Canada, Inc.
- Reason
- Defective container: cracked/broken cartridges
- Recall initiated
- October 31, 2025
- Reported by FDA
- December 24, 2025
- Distribution
- U.S.A. Nationwide
View recall →
Drug Recall
Ongoing
Historical recordClass II
darby dental supply, MEPIVACAINE, Mepivacaine HCI 3% (30mg/mL) Injection, [Mepivacaine HCI Injection, USP], packaged in a carton containing 50 single-dose Cartridges, 1.7 mL each, Rx only, Manufactured by Novocol Pharmaceutical of Canada, Inc., NDC 66467-9760-5.
by Novocol Pharmaceutical of Canada, Inc.
- Reason
- Defective container: cracked/broken cartridges
- Recall initiated
- October 31, 2025
- Reported by FDA
- December 24, 2025
- Distribution
- U.S.A. Nationwide
View recall →
Drug Recall
Ongoing
Historical recordClass II
3% Polocaine DENTAL, Mepivacaine Hydrochloride 3% (30mg/mL) (Mepivacaine HCI Injection, USP), packaged in a carton containing 50 single-dose Cartridges, 1.7 ml each, Rx only, Manufactured for Dentsply Pharmaceutical, York, PA 17404, by Novocol Pharmaceutical of Canada, Inc., NDC 66312-441-16.
by Novocol Pharmaceutical of Canada, Inc.
- Reason
- Defective container: cracked/broken cartridges
- Recall initiated
- October 31, 2025
- Reported by FDA
- December 24, 2025
- Distribution
- U.S.A. Nationwide
View recall →
Drug Recall
Ongoing
Historical recordClass II
Lidocaine HCI 2% and Epinephrine 1:100,000 (Lidocaine HCI and Epinephrine Injection USP), packaged in a carton containing 50 single-dose Cartridges, 1.7 ml each, Rx only, Manufactured for Patterson Dental Supply, Inc., 1031 Mendota Heights Road, Saint Paul, MN55120, Manufactured by: Novocol Pharmaceutical of Canada, Inc., NDC 50227-1030-5.
by Novocol Pharmaceutical of Canada, Inc.
- Reason
- Defective container: cracked/broken cartridges
- Recall initiated
- October 31, 2025
- Reported by FDA
- December 24, 2025
- Distribution
- U.S.A. Nationwide
View recall →
Drug Recall
Ongoing
Historical recordClass II
2% Xylocaine DENTAL with Epinephrine 1:100,000 (Lidocaine HCI and Epinephrine Injection USP), packaged in a carton containing 50 single-dose cartridges, 1.7 mL each, Rx only, Manufactured for Dentsply Pharmaceutical, York, PA 17404, by Novocol Pharmaceutical of Canada, Inc., NDC 66312-176-16.
by Novocol Pharmaceutical of Canada, Inc.
- Reason
- Defective container: cracked/broken cartridges
- Recall initiated
- October 31, 2025
- Reported by FDA
- December 24, 2025
- Distribution
- U.S.A. Nationwide
View recall →
Drug Recall
Ongoing
Historical recordClass II
Sertraline Hydrochloride Tablets USP, 100 mg, 90 Tablets bottles, Rx Only, Manufactured by: Lupin Pharmaceuticals, Inc., Naples, FL 34108, NDC 68180-353-09.
by Lupin Pharmaceuticals Inc.
- Reason
- Defective container - seal not adhering to bottles
- Recall initiated
- November 5, 2025
- Reported by FDA
- December 17, 2025
- Distribution
- Nationwide.
View recall →
Drug Recall
Ongoing
Historical recordClass II
Cinacalcet Hydrochloride Tablets, 90 mg, 30 Tablets per bottle, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-412-02
by Cipla USA, Inc.
- Reason
- CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
- Recall initiated
- November 14, 2025
- Reported by FDA
- December 17, 2025
- Distribution
- Nationwide in the US
View recall →
Drug Recall
Ongoing
Historical recordClass II
Cinacalcet Hydrochloride Tablets, 60 mg, 30 Tablets per bottle, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-411-02
by Cipla USA, Inc.
- Reason
- CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
- Recall initiated
- November 14, 2025
- Reported by FDA
- December 17, 2025
- Distribution
- Nationwide in the US
View recall →
Drug Recall
Ongoing
Historical recordClass II
Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-410-02
by Cipla USA, Inc.
- Reason
- CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
- Recall initiated
- November 14, 2025
- Reported by FDA
- December 17, 2025
- Distribution
- Nationwide in the US
View recall →
Drug Recall
Ongoing
Historical recordClass III
Morphine Sulfate Oral Solution 100 mg / 5 mL (20 mg* / mL), 30 mL, Rx Only, For Oral Use Only, Manufactured By: /winder Laboratories, LLC, Winder, GA 30680. NDC: 75826-131-01
by Winder Laboratories, LLC
- Reason
- Correct Labeled Product Mispack-Size stated on carton label did not match the size of the bottle in the carton.
- Recall initiated
- November 26, 2025
- Reported by FDA
- December 17, 2025
- Distribution
- U.S. Nationwide
View recall →
Drug Recall
Ongoing
Historical recordClass III
Nebivolol Tablets, 20 mg, 90 Tablets, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for Avkare, Pulaski, TN 38478, Product of Italy, NDC 42291-874-90.
by Glenmark Pharmaceuticals Inc., USA
- Reason
- Cross Contamination with Other Products
- Recall initiated
- November 18, 2025
- Reported by FDA
- December 17, 2025
- Distribution
- U.S. Nationwide
View recall →
Drug Recall
Ongoing
Historical recordClass II
Tropicamide 1%/Cyclopentolate 1%/Phenylephrine 2.5%/Ketorolac 0.5% Topical Ophthalmic Solution, 0.5mL Single-Use Syringe, For Topical Ophthalmic Use Only. Not for IV Use. Fagron Sterile Services, 8710 E 34th St N, Wichita, KS 67226. NDC: 71266-8240-01
by Fagron Compounding Services
- Reason
- Incorrect Product Formulation
- Recall initiated
- November 20, 2025
- Reported by FDA
- December 17, 2025
- Distribution
- U.S. Nationwide.
View recall →
Drug Recall
Ongoing
Historical recordClass II
Ganirelix Acetate Injection, 250 mcg/0.5mL, Single-dose Sterile Prefilled Syringe, 27 gauge by 1/2' needle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, United States, Manufactured by: Lupin Limited, Nagpur - 441108, INDIA, NDC 70748-274-01
by Lupin Pharmaceuticals Inc.
- Reason
- Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.
- Recall initiated
- November 13, 2025
- Reported by FDA
- December 17, 2025
- Distribution
- FL, MA, MI & OH
View recall →
Drug Recall
Ongoing
Historical recordClass III
Varenicline Tablets, 1mg, 56 Tablets, Rx only, Distributor: Dr. Reddy's Laboratories Inc., Princeton, NJ 08540, Made in India, NDC 43598-908-56
by Dr. Reddy's Laboratories, Inc.
- Reason
- Sub potent drug: during the 9-month stability test conducted, the assay value for the affected lot was below specification limit.
- Recall initiated
- November 11, 2025
- Reported by FDA
- December 17, 2025
- Distribution
- Distributed Nationwide
View recall →
Drug Recall
Ongoing
Historical recordClass II
Lanthanum Carbonate chewable tablets, 1000mg*, 10x9 bottles per patient pack carton, Rx Only, Manufactured by: Invagen Pharmaceuticals, Inc., (a subsidary of Cipla Ltd) Hauppauge, NY 11786, Manufactured for: Exelan Pharmaceuticals, Inc., Boca Raton, FL 33422, Carton NDC 76282-478-90; Bottle NDC 76282-478-13.
by Cipla USA, Inc.
- Reason
- Failed stability specifications: Out of specification for hardness test
- Recall initiated
- October 24, 2025
- Reported by FDA
- December 17, 2025
- Distribution
- Nationwide in the USA
View recall →
Drug Recall
Ongoing
Historical recordClass II
Lanthanum Carbonate chewable tablets, 1000mg*, 10x9 bottles per patient pack carton, Rx Only, Manufactured by: Invagen Pharmaceuticals, Inc., Hauppauge, NY 11786, Manufactured for : Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-936-98.
by Cipla USA, Inc.
- Reason
- Failed stability specifications: Out of specification for hardness test
- Recall initiated
- October 24, 2025
- Reported by FDA
- December 17, 2025
- Distribution
- Nationwide in the USA
View recall →
This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace
does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice --
always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take.
Read the full medical disclaimer.